PERSPECTIVE THERAPEUTICS, INC. Long-Term Debt, Maturity, Year Three
PERSPECTIVE THERAPEUTICS, INC. (CATX) had Long-Term Debt, Maturity, Year Three of $1.57 million as of 2024-12-31, per its 10-K/A filed 2025-03-28.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree · last filed 2025-03-28
- 2024-12-31: Long-Term Debt, Maturity, Year Three $1.57M.
- 2024-09-30: Long-Term Debt, Maturity, Year Three $1.57M.
- 2024-06-30: Long-Term Debt, Maturity, Year Three $1.57M.
- 2024-03-31: Long-Term Debt, Maturity, Year Three $1.57M.
| Period end | Long-Term Debt, Maturity, Year Three |
|---|---|
| 2024-12-31 | $1.57M 10-K/A · filed 2025-03-28 |
| 2024-09-30 | $1.57M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.57M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.57M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $55.00K 10-K · filed 2024-03-28 |
| 2023-09-30 | $55.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $55.00K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $55.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |